ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $30.00 Price Target at JPMorgan Chase & Co.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price objective upped by JPMorgan Chase & Co. from $26.00 to $30.00 in a report published on Friday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other research firms have also recently commented on ACAD. BMO Capital Markets boosted […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price objective upped by JPMorgan Chase & Co. from $26.00 to $30.00 in a report published on Friday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other research firms have also recently commented on ACAD. BMO Capital Markets boosted […]
